Shaodong Hong

7.0k total citations · 2 hit papers
128 papers, 3.9k citations indexed

About

Shaodong Hong is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Surgery. According to data from OpenAlex, Shaodong Hong has authored 128 papers receiving a total of 3.9k indexed citations (citations by other indexed papers that have themselves been cited), including 101 papers in Oncology, 72 papers in Pulmonary and Respiratory Medicine and 19 papers in Surgery. Recurrent topics in Shaodong Hong's work include Lung Cancer Treatments and Mutations (69 papers), Cancer Immunotherapy and Biomarkers (40 papers) and Lung Cancer Research Studies (40 papers). Shaodong Hong is often cited by papers focused on Lung Cancer Treatments and Mutations (69 papers), Cancer Immunotherapy and Biomarkers (40 papers) and Lung Cancer Research Studies (40 papers). Shaodong Hong collaborates with scholars based in China, United States and United Kingdom. Shaodong Hong's co-authors include Wenfeng Fang, Yan Huang, Hongyun Zhao, Yunpeng Yang, Yuxiang Ma, Yaxiong Zhang, Li Zhang, Li Zhang, Jianhua Zhan and Shiyang Kang and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Shaodong Hong

120 papers receiving 3.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation

2015 534 citations Nan Chen, Wenfeng Fang et al. Journal of Thoracic Oncology profile →
Camrelizumab (SHR-1210) alone or in combination with gemcitabine plus cisplatin for nasopharyngeal carcinoma: results from two single-arm, phase 1 trials

2018 326 citations Wenfeng Fang, Yunpeng Yang et al. profile →

Peers

Countries citing papers authored by Shaodong Hong

Since Specialization

Citations

This map shows the geographic impact of Shaodong Hong's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Shaodong Hong with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Shaodong Hong more than expected).

Fields of papers citing papers by Shaodong Hong

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Shaodong Hong. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Shaodong Hong. The network helps show where Shaodong Hong may publish in the future.

Co-authorship network of co-authors of Shaodong Hong

This figure shows the co-authorship network connecting the top 25 collaborators of Shaodong Hong. A scholar is included among the top collaborators of Shaodong Hong based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Shaodong Hong. Shaodong Hong is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	First‐Line Third‐Generation EGFR Tyrosine Kinase Inhibitor Monotherapy for Advanced EGFR‐Mutated Non‐Small Cell Lung Cancer: A Systematic Review and Network Meta‐Analysis 2025 ·MedComm ·Wei Du, Anlin Li, (unknown), Yunpeng Yang, Wenfeng Fang, Yan Huang, Shaodong Hong, (unknown)	0
2	Phase 1b/2 study of ADG106, a 4-1BB/CD137 agonist, in combination with toripalimab in patients with advanced solid tumors 2025 ·iScience ·(unknown), (unknown), Yongsheng Wang, (unknown), (unknown), Yan Huang, Yuanyuan Zhao, Wenfeng Fang, Shaodong Hong, Yang Zhang, Qianwen Liu, Guizhong Liu, (unknown), Jiping Zha, Songmao Zheng, Yan Li, Peter Luo, (unknown), (unknown)	2
3	Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human Phase I/Ib Study 2025 ·Clinical Cancer Research ·(unknown), Yuxiang Ma, Yuanyuan Zhao, Yongsheng Wang, (unknown), Yan Huang, (unknown), Wenfeng Fang, Shaodong Hong, Yang Zhang, (unknown), (unknown), (unknown), (unknown), Li Zhang, Hongyun Zhao	3
4	Perioperative immunotherapy plus chemotherapy versus chemotherapy alone for patients with resectable pulmonary lymphoepithelioma-like carcinoma 2024 ·Lung Cancer ·(unknown), Xuanye Zhang, Lina Hu, Sha Fu, (unknown), (unknown), Honglin Zhu, Yixin Zhou, Shaodong Hong	0
5	74P A single-center, phase II study of surufatinib combined with toripalimab, pemetrexed(A), and platinum (P) in patients with advanced non-squamous non-small cell lung cancer (nsq-NSCLC) 2023 ·Immuno-Oncology Technology ·Wenfeng Fang, Yunpeng Yang, Yan Huang, (unknown), Yaojun Zhang, Ting Zhou, (unknown), Shen Zhao, Yuxiang Ma, Shaodong Hong, Hongyun Zhao, Li Zhang	1
6	P2.05-10 The Power for PD-L1 Expression to Predict Immune Checkpoint Blockade Outcomes is Determined by Tumor Transcriptome 2023 ·Journal of Thoracic Oncology ·Angela Li, Liaofu Luo, Wei Du, Liang He, Shuyu Fu, Yan Wang, Zhiya Yu, Yalan Yang, Wen‐Feng Fang, Lingjiao Zhang, Shaodong Hong	0
7	STK11/LKB1-Deficient Phenotype Rather Than Mutation Diminishes Immunotherapy Efficacy and Represents STING/Type I Interferon/CD8+ T-Cell Dysfunction in NSCLC 2023 ·Journal of Thoracic Oncology ·Anlin Li, (unknown), Zhixin Yu, Zihui Tan, Lina He, Sha Fu, Mengting Shi, (unknown), (unknown), Zhichao Li, Jiaqing Liu, Yixin Zhou, Wenfeng Fang, Yunpeng Yang, Li Zhang, Shaodong Hong	21
8	Dual blockade of EGFR and VEGFR pathways: Results from a pilot study evaluating apatinib plus gefitinib as a first‐line treatment for advanced EGFR‐mutant non‐small cell lung cancer 2020 ·SHILAP Revista de lepidopterología ·Zhonghan Zhang, Yang Zhang, Fan Luo, Yuxiang Ma, Wenfeng Fang, Jing Zhan, Li Su, Yunpeng Yang, Yuanyuan Zhao, Shaodong Hong, Ting Zhou, Yaxiong Zhang, Shen Zhao, Yan Huang, Hongyun Zhao, Li Zhang	15
9	Efficacy and Tolerability of Erlotinib 100 mg/d vs. Gefitinib 250 mg/d in EGFR-Mutated Advanced Non-small Cell Lung Cancer (E100VG250): An Open-Label, Randomized, Phase 2 Study 2020 ·Frontiers in Oncology ·Shen Zhao, Zhen Zhang, Wenfeng Fang, Yaxiong Zhang, Zhonghan Zhang, Shaodong Hong, Yuxiang Ma, Ting Zhou, Yunpeng Yang, Yan Huang, Hongyun Zhao, Li Zhang	3
10	Comprehensive Genomic Profiling Identifies Novel Genetic Predictors of Response to Anti–PD-(L)1 Therapies in Non–Small Cell Lung Cancer 2019 ·Clinical Cancer Research ·Wenfeng Fang, Yuxiang Ma, Jiani C. Yin, Shaodong Hong, Huaqiang Zhou, Ao Wang, Fufeng Wang, Hua Bao, Xue Wu, Yunpeng Yang, Yan Huang, Hongyun Zhao, Yang Shao, Li Zhang	139
11	The ACTIVE study protocol: apatinib or placebo plus gefitinib as first-line treatment for patients with EGFR-mutant advanced non-small cell lung cancer (CTONG1706) 2019 ·Cancer Communications ·Zhonghan Zhang, Fan Luo, Yang Zhang, Yuxiang Ma, Shaodong Hong, Yunpeng Yang, Wenfeng Fang, Yan Huang, Li Zhang, Hongyun Zhao	18
12	P1.11-09 Risk of Second Primary Malignancy After Non-Small-Cell Lung Cancer: A Competing Risk Nomogram Based on the SEER Database 2019 ·Journal of Thoracic Oncology ·Huaqiang Zhou, Jiayi Shen, Yu Zhang, Yan Huang, Wenfeng Fang, Yunpeng Yang, Shaodong Hong, (unknown), Shen Zhao, (unknown), Zhiyuan Zhang, Jun Liu, Wei Xian, Yuanyuan Zhao, Xue Hou, Yuxiang Ma, Ting Zhou, Hongyun Zhao, Li Zhang	1
13	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis 2018 ·Journal for ImmunoTherapy of Cancer ·Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang	82
14	Progression‐free survival and one‐year milestone survival as surrogates for overall survival in previously treated advanced non‐small cell lung cancer 2018 ·International Journal of Cancer ·Shen Zhao, Zhonghan Zhang, Yaxiong Zhang, Shaodong Hong, Ting Zhou, Yunpeng Yang, Wenfeng Fang, Hongyun Zhao, Li Zhang	8
15	Pretreatment Albumin/Globulin Ratio Predicts the Prognosis for Small-Cell Lung Cancer 2016 ·Medicine ·Ting Zhou, Xiaobo He, Wen‐Feng Fang, Jianhua Zhan, Shaodong Hong, Tao Qin, Yuxiang Ma, Sheng Jin, Ningning Zhou, Yuanyuan Zhao, Yan Huang, Li Zhang	47
16	397PD KRAS mutation-induced upregulation of PD-L1 mediates immune escape in lung adenocarcinoma 2016 ·Annals of Oncology ·Shaodong Hong, (unknown), (unknown), Jun Zhan, (unknown)	1
17	Gemcitabine improves survival in patients with recurrent or metastatic nasopharyngeal carcinoma 2016 ·Chinese Journal of Cancer ·Shaodong Hong, Li Zhang	6
18	Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR-Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients with EGFR Mutation breakdown → 2015 ·Journal of Thoracic Oncology ·Nan Chen, Wenfeng Fang, Jianhua Zhan, Shaodong Hong, Yanna Tang, Shiyang Kang, Yaxiong Zhang, Xiaobo He, Ting Zhou, Tao Qin, Yan Huang, Xianping Yi, Li Zhang	534
19	Efficacy and safety of angiogenesis inhibitors in advanced non-small cell lung cancer: a systematic review and meta-analysis 2014 ·Journal of Cancer Research and Clinical Oncology ·Shaodong Hong, Min Tan, Shouzheng Wang, Shengyuan Luo, Yue Chen, Li Zhang	47
20	The prognostic nutritional index (PNI) predicts overall survival of small-cell lung cancer patients 2014 ·Tumor Biology ·Shaodong Hong, Ting Zhou, Wenfeng Fang, Cong Xue, Zhihuang Hu, Tao Qin, Yanna Tang, Yue Chen, Yuxiang Ma, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Yuanyuan Zhao, Li Zhang	104

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact